Topotecan in the treatment of ovarian cancer

References

• Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin. Surg. Oncol.19, 3–10 (2000).
   PubMed Web of Science ®Google Scholar
• Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol.21, 3194–3200 (2003).
   PubMed Web of Science ®Google Scholar
• du Bois A, Luck HJ, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl Cancer Inst.95, 1320–1329 (2003).
   PubMed Web of Science ®Google Scholar
• McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med.334, 1–6 (1996).
   PubMed Web of Science ®Google Scholar
• Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin–paclitaxel versus cisplatin–cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Natl Cancer Inst.92, 699–708 (2000).
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Bundy B, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med.354, 34–43 (2006).
   PubMed Web of Science ®Google Scholar
• Ozols RF. Update of the NCCN ovarian cancer practice guidelines. Oncology (Williston Park)11, 95–105 (1997).
   PubMedGoogle Scholar
• Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann. Oncol.8, 963–968 (1997).
   PubMed Web of Science ®Google Scholar
• Markman M, Webster K, Zanotti K et al. Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. Gynecol. Oncol.90, 593–596 (2003).
   PubMed Web of Science ®Google Scholar
• Gordon AN, Granai CO, Rose PG et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J. Clin. Oncol.18, 3093–3100 (2000).
   PubMed Web of Science ®Google Scholar
• Gordon AN, Fleagle JT, Guthrie D et al. Recurrent epithelial ovarian carcinoma: a randomized Phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol.19, 3312–3322 (2001).
   PubMed Web of Science ®Google Scholar
• Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol.16, 405–410 (1998).
   PubMed Web of Science ®Google Scholar
• Keldsen N, Havsteen H, Vergote I, Bertelsen K, Jakobsen A. Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a Phase II study. Gynecol. Oncol.88, 118–122 (2003).
   PubMed Web of Science ®Google Scholar
• Sorensen P, Hoyer M, Jakobsen A et al. Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. Gynecol. Oncol.81, 58–62 (2001).
   PubMed Web of Science ®Google Scholar
• Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH. The current status of camptothecin analogues as antitumor agents. J. Natl Cancer Inst.85, 271–291 (1993).
   PubMed Web of Science ®Google Scholar
• Pratesi G, Tortoreto M, Corti C, Giardini R, Zunino F. Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts. Br. J. Cancer71, 525–528 (1995).
   PubMed Web of Science ®Google Scholar
• Burris HA III, Hanauske AR, Johnson RK et al. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J. Natl Cancer Inst.84, 1816–1820 (1992).
   PubMed Web of Science ®Google Scholar
• Houghton PJ, Cheshire PJ, Myers L et al. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother. Pharmacol.31, 229–239 (1992).
   PubMed Web of Science ®Google Scholar
• Creemers GJ, Lund B, Verweij J. Topoisomerase I inhibitors: topotecan and irenotecan. Cancer Treat. Rev.20, 73–96 (1994).
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, Grochow LB, Hendricks CB et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J. Clin. Oncol.10, 647–656 (1992).
   PubMed Web of Science ®Google Scholar
• Saltz L, Sirott M, Young C et al. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J. Natl Cancer Inst.85, 1499–1507 (1993).
   PubMed Web of Science ®Google Scholar
• Verweij J, Lund B, Beijnen J et al. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Ann. Oncol.4, 673–678 (1993).
   PubMed Web of Science ®Google Scholar
• Creemers GJ, Bolis G, Gore M et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European Phase II study. J. Clin. Oncol.14, 3056–3061 (1996).
   PubMed Web of Science ®Google Scholar
• Kudelka AP, Tresukosol D, Edwards CL et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J. Clin. Oncol.14, 1552–1557 (1996).
   PubMed Web of Science ®Google Scholar
• Swisher EM, Mutch DG, Rader JS, Elbendary A, Herzog TJ. Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol. Oncol.66, 480–486 (1997).
   PubMed Web of Science ®Google Scholar
• Bookman MA, Malmstrom H, Bolis G et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label Phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J. Clin. Oncol.16, 3345–3352 (1998).
   PubMed Web of Science ®Google Scholar
• McGuire WP, Blessing JA, Bookman MA, Lentz SS, Dunton CJ. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group Study. J. Clin. Oncol.18, 1062–1067 (2000).
   PubMed Web of Science ®Google Scholar
• Armstrong DK. Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity. Oncologist9, 33–42 (2004).
   PubMed Web of Science ®Google Scholar
• ten Bokkel Huinink W, Gore M, Carmichael J et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol.15, 2183–2193 (1997).
   PubMed Web of Science ®Google Scholar
• Armstrong D, O’Reilly S. Clinical guidelines for managing topotecan-related hematologic toxicity. Oncologist3, 4–10 (1998).
   PubMedGoogle Scholar
• Gore M, ten Bokkel Huinink W, Carmichael J et al. Clinical evidence for topotecan-paclitaxel non-cross-resistance in ovarian cancer. J. Clin. Oncol.19, 1893–1900 (2001).
   PubMed Web of Science ®Google Scholar
• ten Bokkel Huinink W, Lane SR, Ross GA. Long-term survival in a Phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann. Oncol.15, 100–103 (2004).
   Google Scholar
• Gordon AN, Tonda M, Sun S, Rackoff W. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a Phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol. Oncol.95, 1–8 (2004).
   PubMed Web of Science ®Google Scholar
• Meier W, Dubois A, Kuhn, Wet al for the AGO Ovarian Cancer Study Group. Topotecan vs treosulfan in recurrent ovarian cancer (OC) after initial therapy with platinum and paclitaxel. A prospective randomized Phase III study. Proc. Am. Soc. Clin. Oncol.22, 1810 (2003).
   Google Scholar
• Hochster H, Wadler S, Runowicz C et al. Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group. J. Clin. Oncol.17, 2553–2561 (1999).
   PubMed Web of Science ®Google Scholar
• Gore M, Rustin G, Schuller J et al. Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer. Br. J. Cancer84, 1043–1046 (2001).
   PubMed Web of Science ®Google Scholar
• Markman M, Kennedy A, Webster K et al. Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer. Gynecol. Oncol.79, 116–119 (2000).
   PubMed Web of Science ®Google Scholar
• Brown JV III, Peters WA III, Rettenmaier MA et al. Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer. Gynecol. Oncol.88, 136–140 (2003).
   PubMed Web of Science ®Google Scholar
• Miller DS, Blessing JA, Lentz SS, McMeekin DS. Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study. Cancer98, 1664–1669 (2003).
   PubMed Web of Science ®Google Scholar
• Herzog TJ, Powell MA, Rader JS, Gibb R, Mutch DG. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer. Gynecol. Oncol.103(2), 637–641 (2006).
   Google Scholar
• Rose PG, Gordon NH, Fusco N et al. A Phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma. Gynecol. Oncol.78, 228–234 (2000).
   PubMed Web of Science ®Google Scholar
• Hoskins P, Eisenhauer E, Beare S et al. Randomized Phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J. Clin. Oncol.16, 2233–2237 (1998).
   PubMed Web of Science ®Google Scholar
• Homesley HD, Hall DJ, Martin DA et al. A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gynecol. Oncol.83, 394–399 (2001).
   PubMed Web of Science ®Google Scholar
• Hofstra LS, Bos AM, de Vries EG et al. A Phase I and pharmacokinetic study of intraperitoneal topotecan. Br. J. Cancer85, 1627–1633 (2001).
   PubMed Web of Science ®Google Scholar
• Robertson MD, Malpass TW, McGonigle KD, Weiden PL, Muntz H. Phase II study of intraperitoneal topotecan as consolidative therapy in ovarian cancer. J. Clin. Oncol.22, 5077 (2004).
   Web of Science ®Google Scholar
• Andreopoulou E, Chen T, Liebes L et al. Phase I/pharmacology study of Intraperitoneal (IP) 3–5 day topotecan alone and with cisplatin on day 1 for consolidation in ovarian cancer. J. Clin. Oncol.23(16S Pt 1), 5045 (2005).
   Google Scholar
• Bos AM, De Vos FY, de Vries EG et al. A Phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer. Eur. J. Cancer41, 539–548 (2005).
   Google Scholar
• Markman M, Webster K, Zanotti K et al. Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers. Gynecol. Oncol.95, 109–113 (2004).
   PubMed Web of Science ®Google Scholar
• Clarke-Pearson DL, Van Le L, Iveson T, Whitney CW et al. Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer. J. Clin. Oncol.19, 3967–3975 (2001).
   PubMed Web of Science ®Google Scholar
• Gore M, Oza A, Rustin G et al. A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. Eur. J. Cancer38, 57–63 (2002).
   PubMed Web of Science ®Google Scholar
• Greggi S, Salerno MG, D’Agostino G et al. Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer. Oncology60, 19–23 (2001).
   PubMed Web of Science ®Google Scholar
• Sehouli J, Stengel D, Oskay G et al. A Phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy. Ann. Oncol.13, 1749–1755 (2002).
   PubMed Web of Science ®Google Scholar
• Verhaar-Langereis M, Karakus A, van Eijkeren M, Voest E, Witteveen E. Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancer. Int. J. Gynecol. Cancer16, 65–70 (2006).
   PubMed Web of Science ®Google Scholar
• Culine S, Mayeur D, Mayer F et al. Topotecan and paclitaxel in second line treatment of advanced ovarian cancer (AOC): a GINECO Phase II Trial. Proc. Am. Soc. Clin. Oncol.20, 858 (2001).
   Google Scholar
• Chiara S, Tognoni A, Pastrone I et al. Topotecan and ifosfamide as salvage treatment in advanced ovarian cancer. Gynecol. Oncol.93, 474–478 (2004).
   PubMed Web of Science ®Google Scholar
• Hanjani P, Nolte S, Shahin MS. Phase II evaluation of 3-day topotecan with cyclophosphamide in the treatment of recurrent ovarian cancer. Gynecol. Oncol.85, 278–284 (2002).
   PubMed Web of Science ®Google Scholar
• Sehouli J, Sommer H, Klare P et al. A randomized multicenter Phase III trial of topotecan monotherapy versus topotecan + etoposide versus topotecan + gemcitabine for second-line treatment of recurrent ovarian cancer. J. Clin. Oncol.24, 5030 (2006).
   Google Scholar
• Scarfone G, Scambia G, Raspagliesi F et al. A multicenter, randomized, Phase III study comparing paclitaxel/carboplatin (PC) versus topotecan/paclitaxel/carboplatin (TPC) in patients with stage III (residual tumor > 1 cm after primary surgery) and stage IV ovarian cancer (OC). J. Clin. Oncol.24, 5003 (2006).
   Google Scholar
• Bookman MA. GOG0182-ICON5: 5-arm Phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-liposomal doxorubicin (D), or topotecan (T) in patients with advanced stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. J. Clin. Oncol.24, 5002 (2006).
   Google Scholar
• Pfisterer J, Weber B, Reuss A et al. Randomized Phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J. Natl Cancer Inst.98, 1036–1045 (2006).
   PubMed Web of Science ®Google Scholar
• de Placido S, Scambia G, Di Vagno G et al. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J. Clin. Oncol.22, 2635–2642 (2004).
   PubMed Web of Science ®Google Scholar
• Markman M, Liu PY, Wilczynski S et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J. Clin. Oncol.21, 2460–2465 (2003).
   PubMed Web of Science ®Google Scholar